Orlando, USA (19 – 23 October 2019) – Xavant Technology (Pty) Ltd will be exhibiting at the American Society of Anesthesiologists at the Orange County Convention Center in Orlando, USA from 19 to 23 October 2019. The company is expected to announce an important product update at the meeting while showcasing their latest objective NMT…
DetailsHamburg, Germany, 13 – 14 December 2019 – Xavant Technology (Pty) Ltd and Promedia Medizintechnik will be exhibiting at the Norddeutsche Anästhesie-Tage at Hotel Grand Elysée Hamburg, Germany, from 13 – 14 December 2019. Visit the Promedia Medizintechnik booth for a demonstration of the Stimpod NMS450X TOF Monitor’s new features. You can learn more about…
DetailsGarmisch-Partenkirchen, Germany, 18 – 19 October 2019 – Xavant Technology (Pty) Ltd and Promedia Medizintechnik will be exhibiting at the 49th Bayerische Anästhesietage in Garmisch-Partenkirche, Germany, from 18 – 19 October 2019. Visit the Promedia Medizintechnik booth for a demonstration of the Stimpod NMS450X TOF Monitor’s new features. You can learn more about the Stimpod…
DetailsMünster, Germany, 28 – 30 November 2019 – Xavant Technology (Pty) Ltd and Promedia Medizintechnik will be exhibiting at the 51st Münsteraner Anästhesie-Symposium in Münster, Germany from 28 – 30 November 2019. Visit the Promedia Medizintechnik booth for a demonstration of the Stimpod NMS450X TOF Monitor’s new features. You can learn more about the Stimpod…
DetailsBerlin, Germany, 19 – 21 September 2019 – Xavant Technology (Pty) Ltd and Promedia Medizintechnik will be exhibiting at the 21st Capital Congress of the Deutsche Gesellschaft für Anästhesiologie & Intensivmedizin in Berlin, Germany from 19 to 21 September 2019. Visit the Promedia Medizintechnik booth for a demonstration of the Stimpod NMS450X TOF Monitor’s new…
DetailsVienna, Austria, 1 – 3 June 2019 – Xavant Technology (Pty) Ltd will be attending Euroanaesthesia, the European Anaesthesiology Congress in Vienna, Austria from 1 – 3 June. The company, a pioneering developer of Train of Four monitors (TOF Monitors), is set to reveal a brand new technology upgrade for its Stimpod NMS450X TOF Monitor.…
DetailsSan Francisco, USA, 13 October 2018 -Xavant Technology (Pty) Ltd is attending the American Society of Anesthesiologists (ASA) Conference 2018 in San Franciso from 13 to 17 October. The company, who is a leading developer of quantitative neuromuscular transmission monitors (NMT monitors) revealed their latest product for the anesthesiology community, the Stimpod NMS450X. The new…
DetailsNOTTINGHAM, United Kingdom, 9 March 2018 – Xavant Technology (Pty) Ltd is attending the Physio First Conference in Nottingham, the United Kingdom, from 27 to 29 April 2018. The company, who is a leading developer of nerve stimulators for regional and general anesthesia, obtained clearance from the U.S Food and Drug Administration’s (FDA) in June 2017 to distribute…
DetailsSan Diego, United States of America (22 October 2017) – Xavant Technology (Pty) Ltd proud to announce their sponsorship of the 28th Annual Meeting of the Academy of Integrative Pain Management (AIPM).
Pretoria, South Africa – Xavant Technology (Pty) Ltd today announced that the U.S. Food and Drug Administration (FDA) cleared their Stimpod NMS460. With the U.S. patent awarded on proprietary hybrid pulsed radio frequency (PRF) waveform, this non-invasive neuromodulation device is focused on the symptomatic relief and management of chronic intractable pain, as well as an adjunctive…
DetailsThe Stimpod NMS450X+, equipped with two different modalities (AMG and EMG), empowers anaesthesiologists to achieve safer intraoperative control of patients’ neuromuscular blockade. The full case NMT Monitoring enables safe extubation and eliminate residual paralysis in any hospital setting, provider preference and surgery type. This advanced technology empowers clinicians to have a safer and more precise control over the neuromuscular blockade during surgery, aligning with the latest guideline-concordant recommendations for the monitoring of patients for residual paralysis following the administration of a neuromuscular reversal agent. The ASA and ESAIC strongly recommend the use of a quantitative neuromuscular blocking agent monitor in conjunction with neuromuscular blocking agents.
While reversal drugs like Sugammadex are commonly used for NMBA reversal, they are not a foolproof solution and residual paralysis remains a significant concern based on clinical evidence. By incorporating the Stimpod NMS450X+ into their practice, anaesthesiologists can proactively monitor the depth of neuromuscular blockade, significantly reducing the incidence of residual paralysis in patients. This contributes to improved patient outcomes and a safer post-operative recovery.
The Stimpod NMS450X+ offers a cost-effective solution in the OR, PACU and ICU. With its two modalities, AMG and EMG, the device provides flexibility in monitoring options. The only neuromuscular monitoring system available with both AMG and EMG enabling cost control at the point-of-care based on need and specific setting, allowing affordable standardisation across the entire hospital. Cost of Care model, enabling monitoring of all drug usage to ensure optimal use, thus saving on both paralytic and recovery agents. This cost-saving feature ensures efficient resource management without compromising patient safety.
AMG offers the most cost-effective option to implement with a reusable sensor and versatile patient setup options enabling neuromuscular transmission monitoring of the hand, toe or face.
EMG is ideally suited for neuromuscular monitoring of surgeries where tucked hands and arms are required, with optimised performance through a patented, skin-like electrode.
Residual neuromuscular blockade after anaesthesia has been linked to severe complications and adverse outcomes, including increased oxygen desaturation, postoperative pneumonia, airway obstruction, and reintubation. By utilizing the Stimpod NMS450X+ and effectively preventing residual NMB, clinicians can contribute to reduced LOS in hospitals and improve patient recovery rates.
Anaesthesiologists worldwide who have adopted the Stimpod NMS450X+ demonstrate their commitment to following the latest guidelines and best practices in anaesthesia. By incorporating a quantitative NMBA monitor into their practice, clinicians align themselves with the recommendations set forth by the ASA and ESAIC, promoting a higher standard of care and patient safety. By utilizing the Stimpod NMS450X+, anaesthesiologists are a testament to its effectiveness to improve patients outcomes and can contribute to the reduction of adverse events and enhance the recovery process for their patients.
